Benzinga | Jul 28, 2020 08:01AM EDT

Twist Bioscience Highlights Launch Of 2 Coronavirus Antibody Panels To Expedite Research For COVID-19

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of two new SARS-CoV-2 antibody panels designed for research use only.

The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus, the virus that causes COVID-19. The Twist Human anti-ACE2 Antibody Panel includes 48 antibodies that bind with picomolar to nanomolar affinity to the extracellular domain (ECD) of the ACE2 receptor on human cells, the receptor that facilitates entry of SARS-CoV-2 into the cells. Both tools are available online at: https://www.twistbioscience.com/coronavirus-research-tools?tab=new-products.

"We continue to optimize and test several antibodies, and expect to select development candidates for internal development in the summer timeframe," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "By offering panels of fully characterized, competitive antibodies that have the potential to treat COVID-19 to the wider scientific community, we expand the reach of our efficient and targeted antibody discovery platform, expediting the search for effective antibody diagnostic and therapeutic options to help combat the global impact of this disease."

All antibodies in each panel are cloned into human antibody backbones to generate VHH Fc, IgG1 or IgG2 antibodies. Available for research use only (RUO) as a panel, individual antibodies within the panel can be licensed for further therapeutic or diagnostic development. For more information or to order the panels through our eCommerce platform, please visit https://pages.twistbioscience.com/twist-covid19-antibodies.html.